Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.55 |
| ▸ | CDK9 | P50750 | 1/20 | 0.55 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.53 |
| ▸ | BAD | Q92934 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | TPMT | P51580 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29788333 | 1.00 | CCNT1 (0.55) | CCNT1CDK9BCL2L1BADHTT | |
| SCHEMBL28788985 | 0.91 | CA12 (0.57) | CCNT1CDK9BCL2L1BADHTT | |
| SCHEMBL2946107 | 0.86 | PTGS1 (0.55) | HTTLMNAMAPK1RAB9AEGFR | |
| SCHEMBL25125397 | 0.83 | CA1 (0.58) | HTTLMNAMAPK1RAB9AEGFR | |
| SCHEMBL16944406 | 0.81 | LTA4H (0.55) | CCNT1CDK9RAB9AKCNH2 | |
| SCHEMBL29788231 | 0.81 | SRD5A2 (0.59) | EGFRRXRACA12CA1CA2 | |
| SCHEMBL2039483 | 0.81 | SRD5A2 (0.59) | EGFRRXRACA12CA1CA2 | |
| SCHEMBL11540681 | 0.81 | ALDH1A1 (0.53) | LMNA | |
| SCHEMBL1222758 | 0.80 | RXRA (0.58) | EGFRRXRACA1CA2PDE4A | |
| SCHEMBL11689848 | 0.80 | ESR2 (0.56) | KCNH2PDGFRBPDGFRACYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-09-22 | — | — | US | disclosed |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EPICS THERAPEUTICS (BE) | 2020-05-14 | — | — | US | disclosed |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-03-03 | — | — | US | disclosed |
| EP-3610872-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EPICS THERAPEUTICS (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2019-10-03 | — | — | US | disclosed |
| EP-3074008-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATION | EPICS THERAPEUTICS (BE) | 2019-09-04 | — | — | EP | disclosed |
| US-10358416-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2019-07-23 | — | — | US | disclosed |
| US-20180297944-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2018-10-18 | — | — | US | disclosed |
| WO-2011073376-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43) | EUROSCREEN S.A. (BE) | 2011-06-23 | — | — | WO | disclosed |
| US-7378447-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7326731-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1644320-B1 | INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS | LILLY CO ELI (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7265246-B2 | Indane derivates as muscarinic receptor agonists | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070060587-A1 | Indane derivates as muscarinic receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-15 | — | — | US | disclosed |
| US-20060178438-A1 | Muscarinic agonists | ELI LILLY AND COMPANY (IN) | 2006-08-10 | — | — | US | disclosed |
| US-20060154922-A1 | Muscarinic agonists | ELILILLY AND COMPANY (US) | 2006-07-13 | — | — | US | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154922-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | CCNT1 912/4885CDK9 3595/4885BCL2L1 3965/4885 |
| US-20060178438-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | CCNT1 912/4885CDK9 3595/4885BCL2L1 3965/4885 |
| US-20180297944-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | CCNT1 3899/4885CDK9 2969/4885BCL2L1 4164/4885 |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | CCNT1 3899/4885CDK9 2969/4885BCL2L1 4164/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | CCNT1 3899/4885CDK9 2969/4885BCL2L1 4164/4885 |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | CCNT1 4578/4885CDK9 3464/4885BCL2L1 4629/4885 |
| US-10358416-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GIPR, GPR88, GPR119 | CCNT1 4744/4885CDK9 3229/4885BCL2L1 4385/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | CCNT1 3899/4885CDK9 2969/4885BCL2L1 4164/4885 |
| US-20070060587-A1 | Indane derivates as muscarinic receptor agonists | CHRM1, CHRM3, CHRM2 | CCNT1 759/4885CDK9 3292/4885BCL2L1 4339/4885 |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | CCNT1 3892/4885CDK9 3254/4885BCL2L1 4484/4885 |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | CCNT1 3884/4885CDK9 2998/4885BCL2L1 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.